| Project/Area Number |
20591709
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | University of Yamanashi |
|---|
Principal Investigator |
SATOU Eiji University of Yamanashi, 医学部附属病院, 講師 (10235319)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KAWATAKI Tomoyuki 山梨大学, 医学部附属病院, 助教 (20303406)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥130,000 (Direct Cost: ¥100,000、Indirect Cost: ¥30,000)
Fiscal Year 2009: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2008: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | インドールアミン2,3-ジオキシゲナーゼ / グリオーマ / 免疫回避機構 / IDO / malignant glioma / prognosis / glioma / immunohistochemistry / 悪性グリオーマ / western blot法 / RT-PCR法 / 免疫組織染色法 / 免疫抑制作用 |
|---|
| Research Abstract |
Indoleamine 2,3-dioxygenase (IDO) is a tryptophan catabolic enzyme participating in immune tolerance and tumor immune escape process. Recently, IDO expression has been found to correlate with prognosis of malignant tumor, but the involvement of IDO in glioma progression remains unknown. The present study investigated the relationship between IDO expression and histological malignance in glioma. IDO expression rate was compared in each histological grade, and survival analysis in correlation with IDO expression was performed. IDO was expressed in 71 of 74 gliomas with varying intensities. IDO was strongly expressed in malignant gliomas, and weekly in low grade gliomas. Survival analysis by the Kaplan-Meier methods revealed that patients with higher IDO expression tended to have poorer clinical outcome compared with lower IDO expression. The present study suggests that IDO expression in glioma cells promotes tumor malignancy and may affect clinical outcome.
|
